A study to assess the efficacy and safety of transarterial chemoembolization combined with camrelizumab in the treatment of patients with recurrent hepatocellular carcinoma after curative resection
Latest Information Update: 30 Mar 2022
At a glance
- Drugs Camrelizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 30 Mar 2022 New trial record
- 14 Mar 2022 Results published in the BMC Cancer